<!DOCTYPE html><html>

<head>
<meta charset="utf-8">
<title>index</title>
<style type="text/css">
body {
  font-family: Helvetica, arial, sans-serif;
  font-size: 14px;
  line-height: 1.6;
  padding-top: 10px;
  padding-bottom: 10px;
  background-color: white;
  padding: 30px; }

body > *:first-child {
  margin-top: 0 !important; }
body > *:last-child {
  margin-bottom: 0 !important; }

a {
  color: #4183C4; }
a.absent {
  color: #cc0000; }
a.anchor {
  display: block;
  padding-left: 30px;
  margin-left: -30px;
  cursor: pointer;
  position: absolute;
  top: 0;
  left: 0;
  bottom: 0; }

h1, h2, h3, h4, h5, h6 {
  margin: 20px 0 10px;
  padding: 0;
  font-weight: bold;
  -webkit-font-smoothing: antialiased;
  cursor: text;
  position: relative; }

h1:hover a.anchor, h2:hover a.anchor, h3:hover a.anchor, h4:hover a.anchor, h5:hover a.anchor, h6:hover a.anchor {
  background: url(data:image/png;base64,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) no-repeat 10px center;
  text-decoration: none; }

h1 tt, h1 code {
  font-size: inherit; }

h2 tt, h2 code {
  font-size: inherit; }

h3 tt, h3 code {
  font-size: inherit; }

h4 tt, h4 code {
  font-size: inherit; }

h5 tt, h5 code {
  font-size: inherit; }

h6 tt, h6 code {
  font-size: inherit; }

h1 {
  font-size: 28px;
  color: black; }

h2 {
  font-size: 24px;
  border-bottom: 1px solid #cccccc;
  color: black; }

h3 {
  font-size: 18px; }

h4 {
  font-size: 16px; }

h5 {
  font-size: 14px; }

h6 {
  color: #777777;
  font-size: 14px; }

p, blockquote, ul, ol, dl, li, table, pre {
  margin: 15px 0; }

hr {
  background: transparent url(data:image/png;base64,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) repeat-x 0 0;
  border: 0 none;
  color: #cccccc;
  height: 4px;
  padding: 0;
}

body > h2:first-child {
  margin-top: 0;
  padding-top: 0; }
body > h1:first-child {
  margin-top: 0;
  padding-top: 0; }
  body > h1:first-child + h2 {
    margin-top: 0;
    padding-top: 0; }
body > h3:first-child, body > h4:first-child, body > h5:first-child, body > h6:first-child {
  margin-top: 0;
  padding-top: 0; }

a:first-child h1, a:first-child h2, a:first-child h3, a:first-child h4, a:first-child h5, a:first-child h6 {
  margin-top: 0;
  padding-top: 0; }

h1 p, h2 p, h3 p, h4 p, h5 p, h6 p {
  margin-top: 0; }

li p.first {
  display: inline-block; }
li {
  margin: 0; }
ul, ol {
  padding-left: 30px; }

ul :first-child, ol :first-child {
  margin-top: 0; }

dl {
  padding: 0; }
  dl dt {
    font-size: 14px;
    font-weight: bold;
    font-style: italic;
    padding: 0;
    margin: 15px 0 5px; }
    dl dt:first-child {
      padding: 0; }
    dl dt > :first-child {
      margin-top: 0; }
    dl dt > :last-child {
      margin-bottom: 0; }
  dl dd {
    margin: 0 0 15px;
    padding: 0 15px; }
    dl dd > :first-child {
      margin-top: 0; }
    dl dd > :last-child {
      margin-bottom: 0; }

blockquote {
  border-left: 4px solid #dddddd;
  padding: 0 15px;
  color: #777777; }
  blockquote > :first-child {
    margin-top: 0; }
  blockquote > :last-child {
    margin-bottom: 0; }

table {
  padding: 0;border-collapse: collapse; }
  table tr {
    border-top: 1px solid #cccccc;
    background-color: white;
    margin: 0;
    padding: 0; }
    table tr:nth-child(2n) {
      background-color: #f8f8f8; }
    table tr th {
      font-weight: bold;
      border: 1px solid #cccccc;
      margin: 0;
      padding: 6px 13px; }
    table tr td {
      border: 1px solid #cccccc;
      margin: 0;
      padding: 6px 13px; }
    table tr th :first-child, table tr td :first-child {
      margin-top: 0; }
    table tr th :last-child, table tr td :last-child {
      margin-bottom: 0; }

img {
  max-width: 100%; }

span.frame {
  display: block;
  overflow: hidden; }
  span.frame > span {
    border: 1px solid #dddddd;
    display: block;
    float: left;
    overflow: hidden;
    margin: 13px 0 0;
    padding: 7px;
    width: auto; }
  span.frame span img {
    display: block;
    float: left; }
  span.frame span span {
    clear: both;
    color: #333333;
    display: block;
    padding: 5px 0 0; }
span.align-center {
  display: block;
  overflow: hidden;
  clear: both; }
  span.align-center > span {
    display: block;
    overflow: hidden;
    margin: 13px auto 0;
    text-align: center; }
  span.align-center span img {
    margin: 0 auto;
    text-align: center; }
span.align-right {
  display: block;
  overflow: hidden;
  clear: both; }
  span.align-right > span {
    display: block;
    overflow: hidden;
    margin: 13px 0 0;
    text-align: right; }
  span.align-right span img {
    margin: 0;
    text-align: right; }
span.float-left {
  display: block;
  margin-right: 13px;
  overflow: hidden;
  float: left; }
  span.float-left span {
    margin: 13px 0 0; }
span.float-right {
  display: block;
  margin-left: 13px;
  overflow: hidden;
  float: right; }
  span.float-right > span {
    display: block;
    overflow: hidden;
    margin: 13px auto 0;
    text-align: right; }

code, tt {
  margin: 0 2px;
  padding: 0 5px;
  white-space: nowrap;
  border: 1px solid #eaeaea;
  background-color: #f8f8f8;
  border-radius: 3px; }

pre code {
  margin: 0;
  padding: 0;
  white-space: pre;
  border: none;
  background: transparent; }

.highlight pre {
  background-color: #f8f8f8;
  border: 1px solid #cccccc;
  font-size: 13px;
  line-height: 19px;
  overflow: auto;
  padding: 6px 10px;
  border-radius: 3px; }

pre {
  background-color: #f8f8f8;
  border: 1px solid #cccccc;
  font-size: 13px;
  line-height: 19px;
  overflow: auto;
  padding: 6px 10px;
  border-radius: 3px; }
  pre code, pre tt {
    background-color: transparent;
    border: none; }

sup {
    font-size: 0.83em;
    vertical-align: super;
    line-height: 0;
}
* {
	-webkit-print-color-adjust: exact;
}
@media screen and (min-width: 914px) {
    body {
        width: 854px;
        margin:0 auto;
    }
}
@media print {
	table, pre {
		page-break-inside: avoid;
	}
	pre {
		word-wrap: break-word;
	}
}
</style>
<style type="text/css">
/**
 * prism.js default theme for JavaScript, CSS and HTML
 * Based on dabblet (http://dabblet.com)
 * @author Lea Verou
 */

code[class*="language-"],
pre[class*="language-"] {
	color: black;
	text-shadow: 0 1px white;
	font-family: Consolas, Monaco, 'Andale Mono', monospace;
	direction: ltr;
	text-align: left;
	white-space: pre;
	word-spacing: normal;
	word-break: normal;
	line-height: 1.5;

	-moz-tab-size: 4;
	-o-tab-size: 4;
	tab-size: 4;

	-webkit-hyphens: none;
	-moz-hyphens: none;
	-ms-hyphens: none;
	hyphens: none;
}

pre[class*="language-"]::-moz-selection, pre[class*="language-"] ::-moz-selection,
code[class*="language-"]::-moz-selection, code[class*="language-"] ::-moz-selection {
	text-shadow: none;
	background: #b3d4fc;
}

pre[class*="language-"]::selection, pre[class*="language-"] ::selection,
code[class*="language-"]::selection, code[class*="language-"] ::selection {
	text-shadow: none;
	background: #b3d4fc;
}

@media print {
	code[class*="language-"],
	pre[class*="language-"] {
		text-shadow: none;
	}
}

/* Code blocks */
pre[class*="language-"] {
	padding: 1em;
	margin: .5em 0;
	overflow: auto;
}

:not(pre) > code[class*="language-"],
pre[class*="language-"] {
	background: #f5f2f0;
}

/* Inline code */
:not(pre) > code[class*="language-"] {
	padding: .1em;
	border-radius: .3em;
}

.token.comment,
.token.prolog,
.token.doctype,
.token.cdata {
	color: slategray;
}

.token.punctuation {
	color: #999;
}

.namespace {
	opacity: .7;
}

.token.property,
.token.tag,
.token.boolean,
.token.number,
.token.constant,
.token.symbol,
.token.deleted {
	color: #905;
}

.token.selector,
.token.attr-name,
.token.string,
.token.char,
.token.builtin,
.token.inserted {
	color: #690;
}

.token.operator,
.token.entity,
.token.url,
.language-css .token.string,
.style .token.string {
	color: #a67f59;
	background: hsla(0, 0%, 100%, .5);
}

.token.atrule,
.token.attr-value,
.token.keyword {
	color: #07a;
}

.token.function {
	color: #DD4A68;
}

.token.regex,
.token.important,
.token.variable {
	color: #e90;
}

.token.important {
	font-weight: bold;
}

.token.entity {
	cursor: help;
}
</style>
</head>
<body>
<h3 id="toc_0">这是目前收集到的信息，我会更新的。</h3>

<p>我知道这些东西，尤其是相关的专业资料有点太多太深，我贴给你，是想尽快让你你可以和老公可以去了解，我也跟着看。如果有问题，你来问我，我去查。</p>

<p>我现在已经开始感觉信息太多太杂，在我们实验室的讨论组里已经有同学关于是否应该获取过多杂乱信息辩论。对此，我希望你一定要以专业信息为准，网上的信息比较乱，最好能查询专业资料。然后所有的这些专业领域的建议都提到了要以医生的建议为核心，我相信你能理智的对待。</p>

<p><em><strong>2015.1.12</strong></em><br>
<strong>对话：</strong><br>
刘万清，普渡大学教授，癌症分子生物学领域。</p>

<blockquote>
<p>小驹你好！ 首先向你的朋友表达我们的关心和问候。这么年轻得上肺癌很不幸！但也希望她能坚强些，毕竟看起来她的情况极有可能有不错的预后。我不是医生，因而只能从我了解的肺癌的分子方面给一些建议：</p>

<p>她的诊断看上去非常初步，也许会有后续的检查不久会跟上来。但至少有几点信息很重要。一是目前看上去癌症尚未转移，虽然恶化级别未知但倾向于低级的程度，说明手术治疗仍有可能取得不错的效果。根据报告判断，可能手术已完成。二是患者是女性，年龄较低，原发腺癌，我判断她可能不抽烟，因为国内抽烟的女性相对较少。这些因素都与EGFR突变密切相关，在东亚、年轻、非抽烟、女性患者腺癌中，EGFR突变率高达80%。如果是检测阳性，现已有靶向药物（如常见的易瑞沙及特罗凯）有很好效果，可在术后作为跟进治疗。另外，EGFR突变阳性的患者预后已达5年以上，是所有肺癌中预后最好之亚型。虽1-2年后仍有较大几率复发，惟现已有多种靶向药物针对这些复发，届时仍需进一步分子诊断，确定下一步治疗方案。</p>

<p>另外，ALK-EML4突变率虽低，如EGFR突变阴性，则应立即检测之，亦可多种分子标记同时检测更佳，以及时确定靶向药物。现已有Crizotinib针对ALK突变，效果极佳。目前国内仍有困难的是有些靶向药物可能尚未进入常规治疗，但可尝试与相应制药公司申请。惟进口药较贵，不知病人经济状况如何。</p>

<p>关于检测本身，由于ARMs法可能存在假阴性情况，建议测序EGFR外显子18-21，以期较大覆盖。</p>

<p>以上建议仅供参考，还需结合医生综合判断后给出具体治疗方案 </p>
</blockquote>

<p>我的回复 </p>

<blockquote>
<p>&ldquo;谢谢刘万清师兄和柏师姐。
朋友这是刚拿到诊断结果，医生说已经不能做手术了，推荐化疗和靶向药。可能先试一试易瑞沙。
我会跟朋友转达您的建议。希望她能尽快做些基因检测。&rdquo;</p>
</blockquote>

<p>万淸师兄的回复</p>

<blockquote>
<p>&ldquo;看来我的判断倾向保守。建议在进行易瑞沙治疗的同时尽快做EGFR和ALK两种检测已争取时间。&rdquo;</p>

<p>万清</p>
</blockquote>

<p>赵健，UCLA博士后</p>

<blockquote>
<p>Pubmed上搜一下肺癌治疗的guideline, 了解一下还是有用的。<a href="#a1">下载相关资料9-11</a></p>
</blockquote>

<p>吴胜男，上海瑞金医院研究员</p>

<blockquote>
<p>&ldquo;小驹，你朋友好年轻，真遗憾。我婆婆2010年也得了肺癌，非小细胞，晚期没法手术。之后用了紫杉醇类化疗药物，没法耐受。改用易瑞沙，大概三个月后评估发现无效，之后用了贝伐单抗，记得药名是阿瓦斯汀，这个药物效果很好，如果一开始就上这个药或许可以延长生命更多。信息供你参考。每个人情况也不一样。&rdquo;</p>
</blockquote>

<p>汪晓燕，苏州生物科技创投</p>

<blockquote>
<p>&ldquo;在针对五年生存率不到百分之二十的非小细胞肺癌的PD1单抗临床试验中，中期结果分析发现免疫治疗实验组生存率远超化疗紫杉醇对照组，实验马上终止，对照组病人全体改用免疫治疗&rdquo;<br>
&ldquo;这是BMS（百时美施贵宝）的单抗药，在日本好像已经批了。&rdquo;<br>
&ldquo;<a href="http://m.news.bms.com/press-release/checkmate-017-phase-3-study-opdivo-nivolumab-compared-docetaxel-patients-second-line-s?from=groupmessage&amp;isappinstalled=0">BMS的网站发布的消息</a>。&rdquo;</p>
</blockquote>

<p><em><strong>2015.1.8</strong></em><br>
<strong>对话：</strong><br>
“1.靶向药有几种，分别针对哪些类型的癌细胞？<br>
2.癌细胞是否会产生耐药性？<br>
3.服用前需要做哪些检查？”  </p>

<p>谈诤，遗传学分析师。</p>

<blockquote>
<p>我不是医生，只是在做肿瘤的基因检测，个人意见仅供参考。</p>

<ol>
<li>靶向药有很多，按来源可分为单抗和小分子化合物。按作用位点有target EGFR tyrosine kinase的gefitinib （Iressa，易瑞沙）和erlotinib （Tarceva, 特罗凯）， target ROS1， ALK, cMET的crizotinib, target BRAF的vemurafenib,dabrafenib。作用位点相同，但是肿瘤组织来源不同，用药有可能不同。比如vemurafenib and dabrafenib都可以用于BRAF突变的melanoma，但如果是BRAF突变的non small cell lung cancer, guideline推荐dabrafenib，不推荐vemurafenib.</li>
<li><p>耐药性非常普遍。靶向药的副作用一般比化疗放疗小，药物有效是病人的生活质量较好，但是往往几个月一年就会出现耐药性。但是现在也有不少新一代的靶向药针对的就是对老一代靶向药的耐药性。比如EGFR T790M的出现会导致对易瑞沙和特罗凯的耐药，而Afatinib， AZD9291针对的就是EGFR T790M引起的耐药。又比如ceritinib的推出针对的是对crizotinib的耐药。魔高一尺道高一丈，魔再高一些，会有新的道再高一些。</p></li>
<li><p>对于东亚女性，无吸烟史的肺癌往往都是由EGFR突变导致的。还需要检测KRAS mutation， ROS1, ALK translocation, cMET amplification. 当然有条件的话，可以做更多的基因，更全面的检查，有更多option。</p></li>
<li><p>如果不是遗传的突变，母婴传播的肺癌好像不大可能。</p></li>
</ol>

<p>再推荐一个网址：http://www.yuaigongwu.com
国内癌症病人的交流群，易瑞沙特罗凯不一定纳入了医保，可以去问问怎么买印度版的。
癌症到晚期大多很不好治，还是要早发现，早干预。希望癌症的早期筛查方法可以尽早成熟。</p>
</blockquote>

<p>余岚，哥伦比亚大学博士后，浙江大学分子生物学副教授</p>

<blockquote>
<p>&ldquo;2. 会, 3. 除了常规 做个基因检测吧&rdquo;</p>
</blockquote>

<p>刘赟，上海交大生命科学院分子遗传学副教授</p>

<blockquote>
<p>&ldquo;1，很多，小分子靶向药和抗体药太多种，络氨酸激酶通路最多，2，会，3，分子检测&rdquo;<br>
&ldquo;甲醛引起的应该是白血病。&rdquo;<br>
“争取入组<em>阿法替尼</em>实验组 <a href="http://wenku.baidu.com/link?url=1Wzn8T-DDfd822hlasQiRXEYYLha1GJ_HhnT9xpYvW99ftieVQHAjKKr95L0qRqDC6b1zuwtoJNpljZVOBRBFDmWRx-3_73u6WJaatmjw97">相关资料1</a>。”</p>
</blockquote>

<p>汪晓燕，苏州生物科技创投</p>

<blockquote>
<p>&ldquo;1、小分子靶向药，抗体药，2、绝对会，3、测基因突变&rdquo;<br>
“哪种肺癌？非小细胞肺癌的话测基因突变用易瑞沙<a href="http://wenku.baidu.com/link?url=1Wzn8T-DDfd822hlasQiRXEYYLha1GJ_HhnT9xpYvW99ftieVQHAjKKr95L0qRqDC6b1zuwtoJNpljZVOBRBFDmWRx-3_73u6WJaatmjw97">相关资料1</a>”<br>
“海德堡有个癌症治疗中心， 欧洲很多去海德堡” </p>
</blockquote>

<p>赵健, UCLA博士后<br>
提供了大部分资料链接。</p>

<blockquote>
<p>&ldquo;最好能参加临床实验&rdquo;</p>
</blockquote>

<p><strong>检索的关键词：</strong><br>
非小细胞肺癌， Afatinib(阿法替尼)， 基因检测</p>

<p><strong>相关资料：</strong><br>
1. <a href="http://wenku.baidu.com/link?url=1Wzn8T-DDfd822hlasQiRXEYYLha1GJ_HhnT9xpYvW99ftieVQHAjKKr95L0qRqDC6b1zuwtoJNpljZVOBRBFDmWRx-3_73u6WJaatmjw97">Afatinib(阿法替尼)治疗非小细胞肺癌的研究进展</a> (<a href="https://github.com/juvion/targeted_therapy/blob/gh-pages/documents/Afatinib(%E9%98%BF%E6%B3%95%E6%9B%BF%E5%B0%BC)%E6%B2%BB%E7%96%97%E9%9D%9E%E5%B0%8F%E7%BB%86%E8%83%9E%E8%82%BA%E7%99%8C%E7%9A%84%E7%A0%94%E7%A9%B6%E8%BF%9B%E5%B1%95.pdf?raw=true">下载pdf</a>)<br>
2. <a href="http://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=206682862&amp;idx=2&amp;sn=aaa213dc575a2094f7721116fa4ad991&amp;scene=1&amp;key=2f5eb01238e84f7e39694a387ef9dc68a63635fa1e65e023ac400d93c3c039de450f5425e93040111c7adb29a6079e5b&amp;ascene=0&amp;uin=MTI3OTExNQ%3D%3D&amp;devicetype=iMac+MacBookPro10%2C1+OSX+OSX+10.10.1+build(14B25)&amp;version=11000003&amp;pass_ticket=04qVBZTGbZM91kmv3IOtfqAu19O6KOXFk7IEn%2BAZ4kk%3D">EGFR 基因突变和 ALK 融合基因阳性 NSCLC 诊疗指南</a><br>
3. <a href="http://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=208084485&amp;idx=1&amp;sn=5fc597aa383002452fb02285306a9fe7&amp;scene=1&amp;key=2f5eb01238e84f7e9ac8cf2e8cbe7d0edc7043a34ea4565716fb38f9275bc14ddbcd58cdb65fd78f86e4161ba58e0717&amp;ascene=0&amp;uin=MTI3OTExNQ%3D%3D&amp;devicetype=iMac+MacBookPro10%2C1+OSX+OSX+10.10.1+build(14B25)&amp;version=11000003&amp;pass_ticket=04qVBZTGbZM91kmv3IOtfqAu19O6KOXFk7IEn%2BAZ4kk%3D">那些年，FDA批准过的实体肿瘤靶向药物</a><br>
4. <a href="http://m.biodiscover.com/news/industry/113434.html?from=timeline&amp;isappinstalled=0">2014年药物研发最热门靶点逐个述评</a><br>
5. <a href="http://mp.weixin.qq.com/s?__biz=MzA4MjM1NjQxNw==&amp;mid=202242762&amp;idx=1&amp;sn=db635a1154ef17313edf5cddbbbaa7a9&amp;key=2f5eb01238e84f7ed9c3b8e57bdd2353d4cdd8a0b5a9632552ff0aef02f8767f3e0b74c69b9f6d351d1150edf53753cd&amp;ascene=0&amp;uin=MTI3OTExNQ%3D%3D&amp;devicetype=iMac+MacBookPro10%2C1+OSX+OSX+10.10.1+build(14B25)&amp;version=11000003&amp;pass_ticket=04qVBZTGbZM91kmv3IOtfqAu19O6KOXFk7IEn%2BAZ4kk%3D">14种肿瘤抗体靶向药物，你都了解吗？</a><br>
6. <a href="http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-treating-targeted-therapies">Targeted therapies for non-small cell lung cancer</a><br>
7. <a href="http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted">Targeted Cancer Therapies</a><br>
8. <a href="http://en.wikipedia.org/wiki/Targeted_therapy_of_lung_cancer">Wikipedia:Targeted therapy of lung cancer</a>  <a name="a3"></a><br>
9. Treatment of Non-small Cell Lung Cancer Stage I and II ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) <a href="https://github.com/juvion/targeted_therapy/blob/gh-pages/documents/Treatment%20of%20Non-small%20Cell%20Lung%20Cancer%20Stage%20I%20and%20II.pdf?raw=true">(下载pdf)</a><br>
10. Treatment of Non-small Cell Lung Cancer Stage IIIA ACCP Evidence-              Based Clinical Practice Guidelines (2nd Edition) <a href="https://github.com/juvion/targeted_therapy/blob/gh-pages/documents/Treatment%20of%20Non-small%20Cell%20Lung%20Cancer%20Stage%20IIIA.pdf?raw=true">(下载pdf)</a><br>
11. Treatment of Non-small Cell Lung Cancer Stage IV ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) <a href="https://github.com/juvion/targeted_therapy/blob/gh-pages/documents/Treatment%20of%20Non-small%20Cell%20Lung%20Cancer%20Stage%20IV.pdf?raw=true">(下载pdf)</a></p>

<script type="text/javascript">
self=typeof window!="undefined"?window:typeof WorkerGlobalScope!="undefined"&&self instanceof WorkerGlobalScope?self:{};var Prism=function(){var e=/\blang(?:uage)?-(?!\*)(\w+)\b/i,t=self.Prism={util:{encode:function(e){return e instanceof n?new n(e.type,t.util.encode(e.content),e.alias):t.util.type(e)==="Array"?e.map(t.util.encode):e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/\u00a0/g," ")},type:function(e){return Object.prototype.toString.call(e).match(/\[object (\w+)\]/)[1]},clone:function(e){var n=t.util.type(e);switch(n){case"Object":var r={};for(var i in e)e.hasOwnProperty(i)&&(r[i]=t.util.clone(e[i]));return r;case"Array":return e.slice()}return e}},languages:{extend:function(e,n){var r=t.util.clone(t.languages[e]);for(var i in n)r[i]=n[i];return r},insertBefore:function(e,n,r,i){i=i||t.languages;var s=i[e];if(arguments.length==2){r=arguments[1];for(var o in r)r.hasOwnProperty(o)&&(s[o]=r[o]);return s}var u={};for(var a in s)if(s.hasOwnProperty(a)){if(a==n)for(var o in r)r.hasOwnProperty(o)&&(u[o]=r[o]);u[a]=s[a]}t.languages.DFS(t.languages,function(t,n){n===i[e]&&t!=e&&(this[t]=u)});return i[e]=u},DFS:function(e,n,r){for(var i in e)if(e.hasOwnProperty(i)){n.call(e,i,e[i],r||i);t.util.type(e[i])==="Object"?t.languages.DFS(e[i],n):t.util.type(e[i])==="Array"&&t.languages.DFS(e[i],n,i)}}},highlightAll:function(e,n){var r=document.querySelectorAll('code[class*="language-"], [class*="language-"] code, code[class*="lang-"], [class*="lang-"] code');for(var i=0,s;s=r[i++];)t.highlightElement(s,e===!0,n)},highlightElement:function(r,i,s){var o,u,a=r;while(a&&!e.test(a.className))a=a.parentNode;if(a){o=(a.className.match(e)||[,""])[1];u=t.languages[o]}if(!u)return;r.className=r.className.replace(e,"").replace(/\s+/g," ")+" language-"+o;a=r.parentNode;/pre/i.test(a.nodeName)&&(a.className=a.className.replace(e,"").replace(/\s+/g," ")+" language-"+o);var f=r.textContent;if(!f)return;var l={element:r,language:o,grammar:u,code:f};t.hooks.run("before-highlight",l);if(i&&self.Worker){var c=new Worker(t.filename);c.onmessage=function(e){l.highlightedCode=n.stringify(JSON.parse(e.data),o);t.hooks.run("before-insert",l);l.element.innerHTML=l.highlightedCode;s&&s.call(l.element);t.hooks.run("after-highlight",l)};c.postMessage(JSON.stringify({language:l.language,code:l.code}))}else{l.highlightedCode=t.highlight(l.code,l.grammar,l.language);t.hooks.run("before-insert",l);l.element.innerHTML=l.highlightedCode;s&&s.call(r);t.hooks.run("after-highlight",l)}},highlight:function(e,r,i){var s=t.tokenize(e,r);return n.stringify(t.util.encode(s),i)},tokenize:function(e,n,r){var i=t.Token,s=[e],o=n.rest;if(o){for(var u in o)n[u]=o[u];delete n.rest}e:for(var u in n){if(!n.hasOwnProperty(u)||!n[u])continue;var a=n[u];a=t.util.type(a)==="Array"?a:[a];for(var f=0;f<a.length;++f){var l=a[f],c=l.inside,h=!!l.lookbehind,p=0,d=l.alias;l=l.pattern||l;for(var v=0;v<s.length;v++){var m=s[v];if(s.length>e.length)break e;if(m instanceof i)continue;l.lastIndex=0;var g=l.exec(m);if(g){h&&(p=g[1].length);var y=g.index-1+p,g=g[0].slice(p),b=g.length,w=y+b,E=m.slice(0,y+1),S=m.slice(w+1),x=[v,1];E&&x.push(E);var T=new i(u,c?t.tokenize(g,c):g,d);x.push(T);S&&x.push(S);Array.prototype.splice.apply(s,x)}}}}return s},hooks:{all:{},add:function(e,n){var r=t.hooks.all;r[e]=r[e]||[];r[e].push(n)},run:function(e,n){var r=t.hooks.all[e];if(!r||!r.length)return;for(var i=0,s;s=r[i++];)s(n)}}},n=t.Token=function(e,t,n){this.type=e;this.content=t;this.alias=n};n.stringify=function(e,r,i){if(typeof e=="string")return e;if(Object.prototype.toString.call(e)=="[object Array]")return e.map(function(t){return n.stringify(t,r,e)}).join("");var s={type:e.type,content:n.stringify(e.content,r,i),tag:"span",classes:["token",e.type],attributes:{},language:r,parent:i};s.type=="comment"&&(s.attributes.spellcheck="true");if(e.alias){var o=t.util.type(e.alias)==="Array"?e.alias:[e.alias];Array.prototype.push.apply(s.classes,o)}t.hooks.run("wrap",s);var u="";for(var a in s.attributes)u+=a+'="'+(s.attributes[a]||"")+'"';return"<"+s.tag+' class="'+s.classes.join(" ")+'" '+u+">"+s.content+"</"+s.tag+">"};if(!self.document){if(!self.addEventListener)return self.Prism;self.addEventListener("message",function(e){var n=JSON.parse(e.data),r=n.language,i=n.code;self.postMessage(JSON.stringify(t.util.encode(t.tokenize(i,t.languages[r]))));self.close()},!1);return self.Prism}var r=document.getElementsByTagName("script");r=r[r.length-1];if(r){t.filename=r.src;document.addEventListener&&!r.hasAttribute("data-manual")&&document.addEventListener("DOMContentLoaded",t.highlightAll)}return self.Prism}();typeof module!="undefined"&&module.exports&&(module.exports=Prism);
</script>
</body>

</html>
